The Georgetown Lombardi Comprehensive Cancer Center (LCCC) Molecular Oncology Program (MO) brings together investigators whose mission is to identify and validate molecular pathways critical to the initiation, progression, maintenance and metastases of cancer. The overall goals of MO are to understand and develop biomarkers for the complex processes of cancer susceptibility, initiation and progression, plus identify novel targets and novel and repurposed anti-cancer agents that show promise because of reduced toxicity against normal cells. To accomplish this mission and goals, MO members perform research under two 2 aims: 1) Define and exploit unique genomic and epigenomic events that initiate and sustain cancer growth and 2) determine the biological mechanisms that underlie stem cell-like phenotypes, altered metabolism and the metastatic spread of cancer cells. A significant advances that reflects progress in Aim 1 by Yi found that Yap modulates the immunosuppressive environment in pancreatic ductal adenocarcinoma (PDAC).
For Aim 2, Chung identified theaphenon E treatment significantly decreased ?-OHPdG levels in the liver DNA of Xpa-/- mice that reduced HCC incidence in these mice to 14% from 100% in the controls. The LCCC Consortium is comprised of Georgetown Lombardi Comprehensive Cancer Center, based in Washington, DC (LCCC-DC) and the John Theurer Cancer Center of Hackensack Meridian Health, based in Hackensack, NJ (LCCC-NJ). Accordingly, the LCCC catchment area is defined by the LCCC-DC and LCCC0NJ catchment areas. Led by Jeffrey Toretsky, MD and Benjamin Tycko, MD, PhD, the program has 21 members and 23 associate members from 13 departments across LCCC Consortium institutions. In the current year, MO members are supported by $7.68M ($7.3M LCCC-DC, $385,226 LCCC-NJ) in research grant funding (annual direct costs) of which $2.3M ($1.92M LCCC-DC, $385,226 LCCC-NJ) is peer reviewed and $1.251M (at LCCC-DC) is funded by the National Cancer Institute (NCI). MO is home to four multi-investigator grants. Productivity is demonstrated by 214 cancer-related publications, 23 of which were in journals with an impact factor ? 8. Cancer and program-related publications included 23% inter- programmatic, 22% intra-programmatic, 11% inter- and intra-programmatic and 36% that involved collaborations with another cancer center. MO members collaborate with members of the other three LCCC Research Programs (Breast Cancer Program [BC], Cancer Prevention and Control Program [CPC], and Experimental Therapeutics Program [ET]) and use all nine Shared Resources. To support integrated thematic research, MO houses significant novel technical expertise, including conditionally reprogrammed cells (CRCs), Zevatars, and a BiaCore 4000.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA051008-26
Application #
9704651
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
26
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Lee, Yichien; Rodriguez, Olga C; Albanese, Chris et al. (2018) Divergent brain changes in two audiogenic rat strains: A voxel-based morphometry and diffusion tensor imaging comparison of the genetically epilepsy prone rat (GEPR-3) and the Wistar Audiogenic Rat (WAR). Neurobiol Dis 111:80-90
Coia, Heidi; Ma, Ning; Hou, Yanqi et al. (2018) Prevention of Lipid Peroxidation-derived Cyclic DNA Adduct and Mutation in High-Fat Diet-induced Hepatocarcinogenesis by Theaphenon E. Cancer Prev Res (Phila) 11:665-676
Ory, Virginie; Kietzman, William B; Boeckelman, Jacob et al. (2018) The PPAR? agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. Breast Cancer Res Treat 169:47-57
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother 67:195-207
Edwardson, Matthew A; Zhong, Xiaogang; Fiandaca, Massimo S et al. (2018) Plasma microRNA markers of upper limb recovery following human stroke. Sci Rep 8:12558
Kaat, Aaron J; Schalet, Benjamin D; Rutsohn, Joshua et al. (2018) Physical function metric over measure: An illustration with the Patient-Reported Outcomes Measurement Information System (PROMIS) and the Functional Assessment of Cancer Therapy (FACT). Cancer 124:153-160
Maximov, Philipp Y; Abderrahman, Balkees; Fanning, Sean W et al. (2018) Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Mol Pharmacol 94:812-822
Czarnecka, Magdalena; Lu, Congyi; Pons, Jennifer et al. (2018) Neuropeptide Y receptor interactions regulate its mitogenic activity. Neuropeptides :
Gonzalez, Thomas L; Moos, Rebecca K; Gersch, Christina L et al. (2018) Metabolites of n-Butylparaben and iso-Butylparaben Exhibit Estrogenic Properties in MCF-7 and T47D Human Breast Cancer Cell Lines. Toxicol Sci 164:50-59

Showing the most recent 10 out of 1120 publications